STU3 Candidate

This page is part of the FHIR Specification (v1.8.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions

Provenance_biocompute_object_example

This is the narrative for the resource. See also the XML or JSON format. This example conforms to the profile Provenance.

Generated Narrative with Details

id: obj.1001

target: Procedure/example/_history/1.2

period: 06/06/2017 --> (ongoing)

recorded: 09/06/2016 8:12:14 AM

reason: antiviral resistance detection (Details: [not stated] code null = 'null', stated as 'antiviral resistance detection')

policy: https://github.com/common-workflow-language/workflows/blob/master/workflows/lobSTR/lobSTR-workflow.cwl

agent

role: Author (Details: http://hl7.org/fhir/provenance-participant-role code author = 'Author', stated as 'null')

who: Practitioner/f204

agent

role: Author (Details: http://hl7.org/fhir/provenance-participant-role code author = 'Author', stated as 'null')

who: Practitioner/f006

entity

role: quotation

reference: Identify baseline single nucleotide polymorphisms (SNPs[SO:0000694]), insertions[SO:0000667], and deletions[SO:0000045] that correlate with reduced ledipasvir[PubChem:67505836] antiviral drug efficacy in Hepatitis C virus subtype 1

entity

role: quotation

reference: Identify treatment emergent amino acid substitutions[SO:0000048] that correlate with antiviral drug treatment failure

entity

role: quotation

reference: Determine whether the treatment emergent amino acid substitutions[SO:0000048] identified correlate with treatment failure involving other drugs against the same virus

 

 

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.